Cargando…

Maternal outcomes among pregnant women receiving live attenuated influenza vaccine

Please cite this paper as: Toback et al. (2012) Maternal outcomes among pregnant women receiving live attenuated influenza accine. Influenza and Other Respiratory Viruses 6(1), 44–51. Background  Although the live attenuated influenza vaccine (LAIV) prescribing information contains warnings/precauti...

Descripción completa

Detalles Bibliográficos
Autores principales: Toback, Seth L., Beigi, Richard, Tennis, Patricia, Sifakis, Frangiscos, Calingaert, Brian, Ambrose, Christopher S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4941557/
https://www.ncbi.nlm.nih.gov/pubmed/21672166
http://dx.doi.org/10.1111/j.1750-2659.2011.00266.x
_version_ 1782442317558317056
author Toback, Seth L.
Beigi, Richard
Tennis, Patricia
Sifakis, Frangiscos
Calingaert, Brian
Ambrose, Christopher S.
author_facet Toback, Seth L.
Beigi, Richard
Tennis, Patricia
Sifakis, Frangiscos
Calingaert, Brian
Ambrose, Christopher S.
author_sort Toback, Seth L.
collection PubMed
description Please cite this paper as: Toback et al. (2012) Maternal outcomes among pregnant women receiving live attenuated influenza accine. Influenza and Other Respiratory Viruses 6(1), 44–51. Background  Although the live attenuated influenza vaccine (LAIV) prescribing information contains warnings/precautions against use during pregnancy, administration of LAIV to pregnant women does occur. Data regarding maternal outcomes after LAIV administration during pregnancy are limited. Objectives  Maternal outcomes after LAIV vaccination during pregnancy were examined. Methods  Data from a health insurance claims database that covers approximately 50 million individuals were analyzed for the six influenza seasons from 2003–2004 through 2008–2009. Emergency department (ED) visits and hospitalizations occurring within 42 days of vaccination were analyzed by primary diagnosis; outcomes were categorized as cardiopulmonary, obstetric, and other. Cohort characteristics were analyzed using descriptive statistics. Results  Of 834 999 pregnancies identified, 138 (0·017%) were among women who received LAIV vaccinations. Of the 138 pregnant women, 13% were ≤19 years, 67% were 20–34 years, and 20% were ≥35 years of age. Eight events occurred within 42 days of vaccination: one ED visit for bronchitis, two hospitalizations for hyperemesis gravidarum and premature labor, and five ED visits/hospitalizations for common medical conditions. All outcomes identified after LAIV exposure occurred at rates similar to rates in unvaccinated pregnant women reported in the medical literature. Conclusions  Administration of LAIV to pregnant women is rare; the rate has remained constant since 2004–2005. In this cohort, there was no evidence of significant maternal adverse outcomes after receipt of LAIV. These data may offer some reassurance to providers and pregnant women in the event of inadvertent LAIV administration, but do not support the routine use of LAIV in pregnant women.
format Online
Article
Text
id pubmed-4941557
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Blackwell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-49415572016-07-18 Maternal outcomes among pregnant women receiving live attenuated influenza vaccine Toback, Seth L. Beigi, Richard Tennis, Patricia Sifakis, Frangiscos Calingaert, Brian Ambrose, Christopher S. Influenza Other Respir Viruses Original Articles Please cite this paper as: Toback et al. (2012) Maternal outcomes among pregnant women receiving live attenuated influenza accine. Influenza and Other Respiratory Viruses 6(1), 44–51. Background  Although the live attenuated influenza vaccine (LAIV) prescribing information contains warnings/precautions against use during pregnancy, administration of LAIV to pregnant women does occur. Data regarding maternal outcomes after LAIV administration during pregnancy are limited. Objectives  Maternal outcomes after LAIV vaccination during pregnancy were examined. Methods  Data from a health insurance claims database that covers approximately 50 million individuals were analyzed for the six influenza seasons from 2003–2004 through 2008–2009. Emergency department (ED) visits and hospitalizations occurring within 42 days of vaccination were analyzed by primary diagnosis; outcomes were categorized as cardiopulmonary, obstetric, and other. Cohort characteristics were analyzed using descriptive statistics. Results  Of 834 999 pregnancies identified, 138 (0·017%) were among women who received LAIV vaccinations. Of the 138 pregnant women, 13% were ≤19 years, 67% were 20–34 years, and 20% were ≥35 years of age. Eight events occurred within 42 days of vaccination: one ED visit for bronchitis, two hospitalizations for hyperemesis gravidarum and premature labor, and five ED visits/hospitalizations for common medical conditions. All outcomes identified after LAIV exposure occurred at rates similar to rates in unvaccinated pregnant women reported in the medical literature. Conclusions  Administration of LAIV to pregnant women is rare; the rate has remained constant since 2004–2005. In this cohort, there was no evidence of significant maternal adverse outcomes after receipt of LAIV. These data may offer some reassurance to providers and pregnant women in the event of inadvertent LAIV administration, but do not support the routine use of LAIV in pregnant women. Blackwell Publishing Ltd 2011-06-14 2012-01 /pmc/articles/PMC4941557/ /pubmed/21672166 http://dx.doi.org/10.1111/j.1750-2659.2011.00266.x Text en © 2011 Blackwell Publishing Ltd
spellingShingle Original Articles
Toback, Seth L.
Beigi, Richard
Tennis, Patricia
Sifakis, Frangiscos
Calingaert, Brian
Ambrose, Christopher S.
Maternal outcomes among pregnant women receiving live attenuated influenza vaccine
title Maternal outcomes among pregnant women receiving live attenuated influenza vaccine
title_full Maternal outcomes among pregnant women receiving live attenuated influenza vaccine
title_fullStr Maternal outcomes among pregnant women receiving live attenuated influenza vaccine
title_full_unstemmed Maternal outcomes among pregnant women receiving live attenuated influenza vaccine
title_short Maternal outcomes among pregnant women receiving live attenuated influenza vaccine
title_sort maternal outcomes among pregnant women receiving live attenuated influenza vaccine
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4941557/
https://www.ncbi.nlm.nih.gov/pubmed/21672166
http://dx.doi.org/10.1111/j.1750-2659.2011.00266.x
work_keys_str_mv AT tobacksethl maternaloutcomesamongpregnantwomenreceivingliveattenuatedinfluenzavaccine
AT beigirichard maternaloutcomesamongpregnantwomenreceivingliveattenuatedinfluenzavaccine
AT tennispatricia maternaloutcomesamongpregnantwomenreceivingliveattenuatedinfluenzavaccine
AT sifakisfrangiscos maternaloutcomesamongpregnantwomenreceivingliveattenuatedinfluenzavaccine
AT calingaertbrian maternaloutcomesamongpregnantwomenreceivingliveattenuatedinfluenzavaccine
AT ambrosechristophers maternaloutcomesamongpregnantwomenreceivingliveattenuatedinfluenzavaccine